Global Uncomplicated Urinary Tract Infection Market Insights Forecasts to 2030
- The Global Uncomplicated Urinary Tract Infection Market Size was valued at USD 8.4 Billion in 2021
- The Global Uncomplicated Urinary Tract Infection Market is Growing at a CAGR of 3.4% from 2022 to 2030
- The Global Uncomplicated Urinary Tract Infection Market is expected to reach 11.9 USD Billion by 2030
- North America is expected to Grow the fastest during the forecast period
Get more details on this report -
The Global Uncomplicated Urinary Tract Infection Market Size is expected to grow measurable count at a CAGR of 3.4% during the forecast period 2021-2030.
In the global uncomplicated urinary tract infection market, if there are no functional or anatomical abnormalities in the urinary tract, no renal functional impairment, and no concomitant disease that would promote the UTI is an uncomplicated urinary tract infection. Uncomplicated urinary tract infections (UTIs) are among the most often seen infections in the outpatient setting. Acute uncomplicated cystitis (AUC) and acute uncomplicated pyelonephritis (AUP) are two examples include. The updated S3 guideline on uncomplicated UTI takes a forward-looking process to the use of antibiotics in treating this frequent kind of illness. UTIs have various negative financial effects on society. They have an impact on quality of life, family obligations, sexual health, and work performance. Women also have a very high rate of UTI recurrence, which increases the risk of complications such as glandular cystitis, pyelonephritis, urinary sepsis, and even acute renal failure, which can be fatal. To stay competitive among their peers in the urinary tract infection market, top UTI treatment providers are concentrating on growing their manufacturing capacities and signing long-term distribution agreements with significant local distribution firms. According to some estimated studies, urinary tract infections afflict over 150 million people globally. In addition, approximately 10% of women visit one physician in a year for urinary tract infection treatment.
This research report categorizes the market for the Global Uncomplicated Urinary Tract Infection Market analysis market based on various segments and regions and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the global uncomplicated urinary tract infection market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the market.
Global Uncomplicated Urinary Tract Infection Market Report Coverage
|Market Size in 2021:||USD 8.4 Billion|
|Forecast Period 2021-2030 CAGR:||3.4%|
|2030 Value Projection:||USD 11.9 Billion|
|Historical Data for:||2017-2020|
|No. of Pages:||200|
|Tables, Charts & Figures:||100|
|Segments covered:||By Test Type, By Drug, By End Users, By Region, COVID-19 Impact Analysis|
|Companies Covered:||Pfizer, Novartis AG, Cipla Inc., Bayer AG, AstraZeneca, Shionogi & Co. Ltd., GlaxoSmithKline PLC, F. Hoffmann-La Roche Ltd, Stryker, Abbott, Siemens, Sysmex Corporation, Cardinal Health, Danaher, Quidel, Bio-Rad Laboratories, Inc., ACON Labs, Eli Lily Company, Allergan|
|Pitfalls & Challenges:||COVID-19 Empact, Challenge, Future, Growth, & Analysis|
Get more details on this report -
Globally, rise in uncomplicated urinary tract infections, the testing market for them is expected to grow dramatically. Due to the rising prevalence of diabetes in low- and middle-income countries, Urinary tract infection testing market opportunities are expected to grow in the market.
With the increasing incidence of chronic kidney diseases such as bladder cancer and renal failure, Patients use catheters and other drainage devices Increase in the usage of urinary catheters will foster the growth of the urinary tract infection treatment market due to several factors such as extended duration of catheterization, not receiving system therapy of antibiotics, bacterial colonization in drainage bags, rapid fatal underlying diseases, and others, are likely to result in catheter-associated urinary tract infection. Antibiotics are the only treatment options available for urinary tract infections. According to the severity of the infection, a wide range of antibiotics is prescribed. For example, fluoroquinolones, trimethoprim/sulfamethoxazole, and aminoglycosides drugs are prescribed as initial treatment for uncomplicated urinary tract infection
The global uncomplicated urinary tract infection therapeutics market growth is held due to a Lack of awareness among people, in developing and underdeveloped countries. The adverse effect of medication used in UTI infection also affects the growth of the market. For example, the drug fluoroquinolone causes variations in blood sugar levels and central nervous system problems such as insomnia, seizures, and anxiety may impact the growth of the global uncomplicated urinary tract infection market over the forecast period.
In 2021, urinalysis is dominating the market with the largest market share over the forecast period.
Based on Test type, the global uncomplicated urinary tract infection market is segmented into Urinalysis, Urine Cultures, and Susceptibility Testing among these, the urinalysis segment is dominating the market due to the demand for urinalysis is projected due to the geriatric population and aging society worldwide. Urinalysis examines different aspects of the urine sample including chemical, microscopic, and visual. Urinalysis is mostly used by healthcare providers to diagnose urinary tract infections (UTIs) along with liver and kidney problems and diabetes.
In 2021, the cystitis segment is witnessing the fastest market share over the forecast period.
Based on the infection type, the global uncomplicated urinary tract infection market is segmented into Urethritis, Cystitis, and Pyelonephritis, among these, the cystitis segment is witnessing the fastest market growth. Cystitis has mostly occurred in women. This uncomplicated cystitis gets cured on its own, if the disease increases then may be antibiotics required for treatment. This is explained by the high incidence and reappearance rate of cystitis, the rise in product approvals, and the large proportion of diabetes patients who are more vulnerable to cystitis. Almost 25% of women get current cystitis within six months of their initial UTI, and the likelihood of cystitis rises in women who have had one or more prior UTIs. In 2021, the quinolones segment has projected the market with the largest market share over the forecast period.
In 2021, the quinolones segment has projected the market with the largest market share over the forecast period.
Based on a drug, the global uncomplicated urinary tract infection market is segmented into Penicillin Combinations, Quinolones, Cephalosporin, Azoles and Amphotericin B, Nitrofurans, and Other Drugs among these, the Quinolones are projected to lead the way in urinary tract infection market during the forecast period. Many doctors suggest that to take quinolones on time to clear the infection. Moreover, for the treatment of urinary tract infections, quinolones stand as a safe and natural substitute to trimethoprim-sulfamethoxazole drug when resistance becomes an issue.
Regional Segment Analysis of the Global Immuno-Oncology Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
North America is dominating the market with the largest market share 0f 43.5% during the forecast period
Get more details on this report -
The North American region has dominated the market and generated the 43.5% of the global market share over the forecast period owing to the rising occurrence of kidney stones, diabetes, and the increasing aging population in this region. This can be assigned to the high disease burden, availability of infrastructure, increased healthcare expenditure, rapid technological advancements, proactive government initiatives, rise in patient awareness, and presence of major players.
Asia Pacific is also expected to drive market growth due to the presence of several large pharmaceutical companies operating in this region. Due to the increasing disease incidence rate especially in pregnant women, increasing the cost-effective diagnostics, growing population, and high aging population during the forecast period.
The report offers the appropriate analysis of the key organizations/companies involved within the Global Uncomplicated Urinary Tract Infection Market analysis along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- Novartis AG
- Cipla Inc.
- Bayer AG
- Shionogi & Co. Ltd.
- GlaxoSmithKline PLC
- F. Hoffmann-La Roche Ltd
- Abbott, Siemens
- Sysmex Corporation
- Cardinal Health
- Bio-Rad Laboratories, Inc.
- ACON Labs
- Eli Lily Company
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
- In September 2021, BDR Pharma launched biapenem for the treatment of patients with intra-abdominal infections, lower respiratory infections, or uncomplicated urinary tract infections.
- In October 2021, Spero Therapeutics Inc. submitted a new drug application to the U.S. Food and Drug Administration (USFDA), seeking approval for tebipenem HBr tablets for the treatment of urinary tract infections, including pyelonephritis, caused by susceptible microorganisms.
- In August 2020, researchers at the California Polytechnic State University originated a new class of antibiotics for urinary tract infections (UTIs), which targets bacterial iron acquisition, at the American Chemical Society conducted Virtual Meeting 2020.
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global uncomplicated urinary tract infection market based on the below-mentioned segments:
Global Uncomplicated Urinary Tract Infection Market, By test type
- Urine Cultures
- Susceptibility Testing
Global Uncomplicated Urinary Tract Infection Market, By infection type
Global Uncomplicated Urinary Tract Infection Market, By Drugs
- Azoles and Amphotericin B,
- Other Drugs
Global Uncomplicated Urinary Tract Infection Market, By End Users
- Diagnostic Laboratories
- Research Institutes
Global Uncomplicated Urinary Tract Infection Market, Regional Analysis
- North America
- U. K.
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
Need help to buy this report?